Moreover, our previous studies revealed that reduced IGFBP-3 expression is a frequent event in the early stage of NSCLC, which correlated with the disease-specific survival probability of stage I NSCLC patients (p = 0.02) [66]. This evidence concerns the gene IGFBP3 and non-small cell lung carcinoma.